Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Sifat SharminFrancesca BovisCharles MalpasDana HorakovaEva Kubala HavrdovaGuillermo IzquierdoSara EichauMaria TrojanoAlexandre PratMarc GirardPierre DuquetteMarco OnofrjAlessandra LugaresiFrancois Grand'MaisonPierre GrammondPatrizia SolaDiana FerraroMurat TerziOliver GerlachRaed AlroughaniCavit BozVahid ShaygannejadVincent van PeschElisabetta CartechiniLudwig KapposJeannette Lechner-ScottRoberto BergamaschiRecai TurkogluClaudio Marcello SolaroGerardo IulianoFranco GranellaBart Van WijmeerschDaniele SpitaleriMark SleePamela McCombeJulie PrevostRadek AmpapaSerkan OzakbasJose Luis Sanchez-MenoyoAysun SoysalSteve VucicThor PetersenKoen de GansErnest ButlerSuzanne HodgkinsonYoussef SidhomRiadh GoudierEdgardo CristianoTamara Castillo-TriviñoMaria Laura SaladinoMichael BarnettFraser MooreCsilla RozsaBassem YamoutOlga SkibinaAnneke van der WaltKatherine BuzzardOrla GrayStella HughesAngel Perez SempereBhim SinghalYara Dadalti FragosoCameron ShawAllan KermodeBruce TaylorMagdolna SimoNeil ShueyTalal Al-HarbiRichard MacdonellJose Andres DominguezTunde CsepanyCarmen Adella SirbuMaria Pia SormaniHelmut ButzkuevenTomas KalincikPublished in: European journal of neurology (2022)
Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.